Meeting
2020 Genitourinary Cancers Symposium
Differences in the exposure to sunitinib in the immediate and deferred cytoreductive nephrectomy (CN) arms of the randomized controlled trial SURTIME.
Authors
Yasmin Abu-Ghanem
Sheba Medical Center, Ramat Gan, Israel
Yasmin Abu-Ghanem , Johannes V. Van Thienen , Christian U. Blank , Thomas Powles , Bertrand F. TOMBAL , Laurence Collette , John B. A. G. Haanen , Axel Bex
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT01099423
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 703)
Abstract #
703
Poster Bd #
H1
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
Prognostic value of simple blood biomarkers of systemic inflammation for metastatic renal cell carcinoma (mRCC) patients who undergo cytoreductive nephrectomy (CNx).
First Author: Jigi Moudgil-Joshi
Poster
2019 Genitourinary Cancers Symposium
Patient perspectives on cytoreductive nephrectomy after CARMENA.
First Author: Dena Battle
Poster
2024 ASCO Genitourinary Cancers Symposium
Systemic and surgical treatment in renal cell carcinoma: Does timing matter?
First Author: Konstantin Egon Seitzer
Poster
2024 ASCO Genitourinary Cancers Symposium
Linear muscle segmentation for metastatic renal cell carcinoma.
First Author: Edouard Nicaise